Hemophilia A Therapeutics - Global Market Outlook to 2023 with Bayer, CSL, Novo Nordisk, Pfizer and Shire Dominating - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 7, 2019--The “Global Hemophilia A Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The hemophilia A therapeutics market will register a CAGR of almost 7% by 2023.
Emerging novel convenient approaches to drive market growth
Several novel therapies are emerging in the global hemophilia A therapeutics market. These therapies offer long lasting therapeutics benefits and some of the m possess potential to cure this disorder.
Rising prevalence of hemophilia A
Hemophilia A is a rare genetic disorder, and the incidence of this disorder is gradually increasing. Hemophilia A accounts for about 80% of cases globally and mainly affects men.
High costs of hemophilia A therapeutics
High costs associated with drugs that treat hemophilia A are one of the biggest challenges faced by the market.
Key PlayersBayer CSL Novo Nordisk Pfizer Shire
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZINGMarket definition Market sizing 2018 Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCTMarket segmentation by product Comparison by product Recombinant therapies - Market size and forecast 2018-2023 Plasma-derived therapies - Market size and forecast 2018-2023 Hormonal therapies - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPEOn demand treatment Prophylactic treatment Inhibitor treatment
PART 10: GEOGRAPHIC LANDSCAPEGeographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPEOverview Landscape disruption
PART 14: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Bayer CSL Novo Nordisk Pfizer Shire
For more information about this report visit https://www.researchandmarkets.com/research/bkvl62/hemophilia_a?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190107005513/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/07/2019 06:07 AM/DISC: 01/07/2019 06:07 AM